腺結合病毒載體生產市場規模、佔有率和成長分析：按血清型、生產系統、規模、最終用戶和地區分類－2026-2033年產業預測

2024 年全球腺結合病毒(AAV) 載體生產市場價值為 15.2 億美元，預計到 2033 年將從 2025 年的 17.9 億美元成長至 65.2 億美元，預測期（2026-2033 年）的複合年成長率為 17.52%。

全球腺結合病毒(AAV) 載體生產市場正受到基因治療進展和監管批准不斷增加的顯著影響，這些進展支撐了商業性可行性。可靠且擴充性的AAV 載體供應對於將治療性基因遞送至患者至關重要。在基因治療成功的推動下，AAV 載體的生產正從小規模學術實驗室轉向專業的合約研發生產機構。諸如適用於懸浮培養的細胞株和一次性生物反應器等創新技術正在湧現，以在保持成本效益和可重複性的同時擴大生產規模。這些調查方法降低了成本，並使企業能夠針對更廣泛的適應症，例如血友病。此外，人工智慧的整合透過製程最佳化和產量提升提高了效率，最終縮短了研發週期，並使全球患者更容易獲得新的治療方法。

全球腺結合病毒（AAV）載體生產市場按血清型、生產系統、規模、最終用戶和地區進行細分。依血清型分類，市場分為AAV2、AAV5、AAV8、AAV9和其他類型。依生產系統分類，市場分為桿狀病毒/昆蟲細胞、三重轉染（HEK293）及單純皰疹病毒（HSV）轉染。依規模分類，市場分為臨床前/研究、臨床（I-III期）及商業化。依最終用戶分類，市場分為基因治療公司、研究機構和合約研發生產機構（CDMO）。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球腺結合病毒載體生產市場的成長要素

基因療法的日益普及顯著提升了腺結合病毒載體的重要性，使其成為遞送治療藥物的首選方法。為了滿足激增的需求，製造商正在加強其專業生產能力並努力改進製程。這種需求的成長推動了對先進製造技術的投資，促進了研發人員與契約製造（CMO）之間的合作，並最終擴大了整個供應鏈的產能。隨著治療藥物研發人員將永續的載體供應放在首位，長期採購合約變得越來越普遍。這使得製造商能夠在不斷變化的環境中預測需求，並透過技術進步和客製化服務做出回應，從而推動市場擴張。

全球腺結合病毒載體生產市場的限制因素

腺結合病毒載體生產的固有複雜性對市場成長構成重大挑戰。上游和下游製程的複雜性要求使用專用設備、熟練人員和嚴格的製程控制，以確保產品品質的穩定性。這些要求對新參與企業構成了巨大的進入門檻，使得產能的快速擴張變得困難。當企業試圖擴張時，往往會面臨更大的複雜性，需要漫長的研發和檢驗週期。因此，製造商和贊助商這種謹慎的投資策略可能會阻礙供應跟上治療方案日益成長的需求。

全球腺結合病毒（AAV）載體生產市場趨勢

全球腺結合病毒（AAV）載體生產市場正經歷著向一次性生物製程的轉型，其驅動力在於市場對更高柔軟性和更低交叉污染風險的需求。這一趨勢使企業能夠透過加速產能擴張和最大限度縮短換線時間，快速將各種載體產品推向市場。向分散式生產模式的轉變不僅減少了傳統不銹鋼設備所需的大量資本投資，還降低了營運挑戰，使小規模的企業也能進入基因治療生產領域。供應商和研發商之間的合作進一步提高了一次性產品和封閉式系統的可用性和效率，最終縮短了創新治療方法的上市時間。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球腺結合病毒載體生產市場規模：依血清型分類

• AAV2
• AAV5
• AAV8
• AAV9
• 其他

全球腺結合病毒載體生產市場規模：依生產系統分類

• 桿狀病毒與昆蟲細胞
• 三重轉染（HEK293）
• 單純皰疹病毒（HSV）

全球腺結合病毒載體生產市場規模：依市場規模分類

• 臨床前和研究
• 臨床（I-III期）
• 商業的

全球腺結合病毒載體生產市場規模：依最終用戶分類

• 基因治療公司
• 研究機構
• CDMO

全球腺結合病毒載體生產市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lonza Group
• Thermo Fisher Scientific（Brammer Bio）
• REGENXBIO Inc.
• Spark Therapeutics（Roche）
• Vigene Biosciences
• Charles River Laboratories
• Andelyn Biosciences
• Forge Biologics
• 4D Molecular Therapeutics
• Genezen Laboratories
• VGXI Inc.
• Puresyn Inc.
• PTC Therapeutics
• Biogen（gene therapy division）
• Oxford Biomedica plc
• Sarepta Therapeutics
• AveXis（Novartis）
• Asklepios Biopharmaceutical
• Passage Bio
• Astellas Gene Therapies

結論與建議

Global Adeno-Associated Virus Vector Manufacturing Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.79 Billion in 2025 to USD 6.52 Billion by 2033, growing at a CAGR of 17.52% during the forecast period (2026-2033).

The global adeno-associated virus (AAV) vector manufacturing market is significantly influenced by advancements in gene therapy and increasing regulatory approvals that validate commercial viability. The demand for reliable, scalable AAV vector supply is critical for delivering therapeutic genes to patients. Production has transitioned from small academic labs to specialized contract development and manufacturing organizations, driven by the success of gene therapies. To maintain affordability and reproducibility while scaling production, innovative techniques such as suspension-adapted cell lines and single-use bioreactors have emerged. These methodologies lower costs, enabling companies to target broader indications like hemophilia. Furthermore, AI integration enhances efficiency by optimizing process conditions and improving yield, ultimately accelerating timelines and enhancing patient access to emerging therapies worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Adeno-Associated Virus Vector Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Adeno-Associated Virus Vector Manufacturing Market Segments Analysis

The global adeno-associated virus vector manufacturing market is segmented by serotype, production system, scale, end-user and region. Based on serotype, the market is segmented into AAV2, AAV5, AAV8, AAV9 and Others. Based on production system, the market is segmented into Baculovirus-Insect Cell, Triple Transfection (HEK293) and Herpes Simplex Virus (HSV). Based on scale, the market is segmented into Preclinical/Research, Clinical (Phase I-III) and Commercial. Based on end-user, the market is segmented into Gene Therapy Companies, Research Institutes and CDMOs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Adeno-Associated Virus Vector Manufacturing Market

The growing interest in gene therapies significantly enhances the importance of adeno-associated virus vectors, establishing them as the preferred method for delivering therapeutic agents. In response to this surge in demand, manufacturers are intensifying their specialized production capabilities while striving to enhance their processes. This escalating need fuels investments in advanced manufacturing technologies and fosters collaborations between developers and contract manufacturers, ultimately expanding capacity across the entire supply chain. As therapeutic developers prioritize sustainable vector supply, they often commit to long-term procurement agreements, which drive market expansion by enabling manufacturers to anticipate requirements and adapt through technological advancements and tailored service offerings, even amidst evolving circumstances.

Restraints in the Global Adeno-Associated Virus Vector Manufacturing Market

The complexity inherent in adeno-associated virus vector manufacturing poses significant challenges that hinder market growth. The intricacies of both upstream and downstream processes necessitate specialized equipment, skilled personnel, and strict process controls to ensure consistent product quality. These requirements create substantial entry barriers for new companies and complicate the rapid scaling of capacity. As organizations attempt to expand, they often encounter additional complexities that necessitate extensive developmental and validation cycles. Consequently, this cautious approach to investment by manufacturers and sponsors can impede the pace at which supply meets the increasing demand for therapeutic solutions.

Market Trends of the Global Adeno-Associated Virus Vector Manufacturing Market

The Global Adeno-Associated Virus (AAV) Vector Manufacturing market is undergoing a transformative shift towards single-use bioprocessing, driven by the demand for greater flexibility and reduced risk of cross-contamination. This trend facilitates rapid scaling of production capabilities and minimizes changeover times, allowing companies to swiftly introduce a wide array of vector products. The move towards decentralized production models not only decreases the hefty capital investment traditionally required for stainless steel facilities but also empowers smaller organizations to enter the gene therapy manufacturing arena with fewer operational challenges. Collaborations between suppliers and developers are further enhancing the accessibility and efficiency of disposables and closed systems, ultimately improving time-to-market for innovative therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Adeno Associated Virus Vector Manufacturing Market Size by Serotype & CAGR (2026-2033)

• Market Overview
• AAV2
• AAV5
• AAV8
• AAV9
• Others

Global Adeno Associated Virus Vector Manufacturing Market Size by Production System & CAGR (2026-2033)

• Market Overview
• Baculovirus-Insect Cell
• Triple Transfection (HEK293)
• Herpes Simplex Virus (HSV)

Global Adeno Associated Virus Vector Manufacturing Market Size by Scale & CAGR (2026-2033)

• Market Overview
• Preclinical/Research
• Clinical (Phase I-III)
• Commercial

Global Adeno Associated Virus Vector Manufacturing Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Gene Therapy Companies
• Research Institutes
• CDMOs

Global Adeno Associated Virus Vector Manufacturing Market Size & CAGR (2026-2033)

• North America (Serotype, Production System, Scale, End-User)
  • US
  • Canada
• Europe (Serotype, Production System, Scale, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Serotype, Production System, Scale, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Serotype, Production System, Scale, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Serotype, Production System, Scale, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (Brammer Bio)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vigene Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Andelyn Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Forge Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 4D Molecular Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genezen Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VGXI Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Puresyn Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (gene therapy division)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Biomedica plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AveXis (Novartis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asklepios Biopharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Passage Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Gene Therapies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations